R-2487
- Generic Name
- R-2487
Rheumatoid Arthritis Market Set to Reach $34.7 Billion by 2035, Driven by Novel Therapies and Rising Obesity Rates
• The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies.
• Rising obesity rates, sedentary lifestyles, and urbanization are significantly contributing to increased rheumatoid arthritis prevalence, while also reducing the efficacy of some treatments.
• Novel treatment approaches including JAK inhibitors, monoclonal antibodies, and emerging therapies like R-2487 and IMVT-1402 are transforming the treatment landscape with more targeted mechanisms of action.
Rise Therapeutics Advances Oral Immunotherapies R-2487 and R-3750 to Dose Expansion
• Rise Therapeutics has completed the dose escalation stages for R-2487 and R-3750 clinical trials, advancing both oral immunotherapies to dose expansion.
• R-2487 is being evaluated for rheumatoid arthritis, aiming to modulate T regulatory cells and reduce inflammatory cytokines.
• R-3750 is under investigation for ulcerative colitis, seeking to reduce gut inflammation and improve intestinal barrier integrity.
• These trials aim to identify novel biomarkers and position the drugs for early intervention in disease progression.
Rise Therapeutics Initiates Phase 1 Trial of R-2487 for Rheumatoid Arthritis
• Rise Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating R-2487 for rheumatoid arthritis, marking a key milestone for the company.
• The Phase 1 trial (NCT05961592) aims to assess the safety, pharmacodynamics, and clinical activity of R-2487, a novel oral immunotherapeutic, in RA patients.
• Rheumatoid arthritis, a chronic inflammatory disorder, affects up to 1% of the US population, with women being disproportionately affected.
• R-2487 represents a commitment to deliver innovative new medicines to the clinical community.
Rise Therapeutics' Oral Immunotherapy R-2487 Cleared for Phase 1 Trial in Rheumatoid Arthritis
• Rise Therapeutics received FDA clearance for its IND application to begin a Phase 1 clinical trial of R-2487, an oral immunotherapy for rheumatoid arthritis.
• R-2487 is designed to induce regulatory T cells (Tregs) and restore immune balance in patients suffering from autoimmune disorders like rheumatoid arthritis.
• The Phase 1 trial will assess the safety, tolerability, drug exposure, and clinical activity of R-2487 in up to 36 rheumatoid arthritis patients.
• Rise Therapeutics aims to validate its synthetic biology platform for oral delivery of biologics, potentially reducing treatment costs and improving ease of administration.
Rise Therapeutics Advances Oral Immunotherapies Across Multiple Phase 1 Trials
• Rise Therapeutics is currently conducting a Phase 1 clinical trial for R-3750, an oral immune therapy, in patients with mild to moderate ulcerative colitis.
• A Phase 1 clinical trial is underway for R-2487, a targeted oral immune therapy designed to induce T regulatory cell populations, in patients with mild to moderate rheumatoid arthritis.
• Rise Therapeutics has initiated a double-blind, placebo-controlled clinical trial to assess the safety and efficacy of R-5280 in newly diagnosed type 1 diabetes patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath